CURRENT APPROACHES TO PREVENT AND DIAGNOSE CONGENITAL TOXOPLASMOSIS: THE ITALIAN EXPERIENCE

Authors

  • Chiara Salvottini Hospital for Mother and Child, Department of Pediatrics, University of Verona, Verona, Italy
  • Marco Caminati General Hospital, Asthma Center and Allergy Unit, University of Verona, Verona, Italy
  • Valeria Meroni Department of Internal Medicine and Medical Therapy, University of Pavia, Microbiology and Virology Unit Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

DOI:

https://doi.org/10.46793/PP180307009S

Keywords:

Toxoplasmosis, diagnosis, IGRA test, newborns, pregnancy

Abstract

Congenital toxoplasmosis is an important cause of morbidity and mortality in congenitally infected newborns: even if the classic triad of hydrocephalus, intracranial calcifications and chorioretinitis  is  almost a remnant from the past, the infection can still cause retinal disease during childhood or adolescence.  Preventive strategies and a correct diagnosis in pregnant women and in newborns are very important. The infection usually runs asymptomatic and the diagnosis relies primarily on serological tests. In pregnant women the differential diagnosis between early seroconversion and false positive IgM is always puzzling. The diagnosis of congenital toxoplasmosis at birth is usually a complicated task; the decision to treat with potentially harmful compounds relies exclusively on laboratory findings (either the detection of anti-Toxoplasma IgM and IgA, or the detection of persistent production of specific IgG during the first year of life) and their interpretation can be challenging when they give heterogeneous results. Researchers are trying to develop new tests that exploit the cellular immunity involved during the course of the infection like an interferon-gamma release assay similar to the Quantiferon for Mycobacterium tuberculosis.

References

Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. International journal for parasitology. 2009;39 (12):1385-1394. DOI: 10.1016/j.ijpara.2009.04.003.

de Jong EP, Vossen AC, Walther FJ, Lopriore E. How to use... neonatal TORCH testing. Arch Dis Child Educ Pract Ed. 2013 Jun; 98(3):93-8. doi: 10.1136/archdischild-2012-303327. DOI: 10.1136/archdischild-2012-303327.

Mosti M, Pinto B, Giromella A et al. A 4-year evaluation of toxoplasmosis seroprevalence in the general population and in women of reproductive age in central Italy. Epidemiology and infection. 2013;141(10):2192-2195. DOI: 10.1017/S0950268812002841.

Tomasoni LR, Meroni V, Bonfanti C et al. Multidisciplinary approach to congenital Toxoplasma infection: an Italian nationwide survey. New Microbiol 2014;37(3):347-354. PMID:25180849.

Kijlstra A, Jongert E. Toxoplasma-safe meat: close to reality? Trends in parasitology 2009;25(1):18-22. DOI: 10.1016/j.pt.2008.09.008.

Wilson C, Nizet V, Maldonado Y, Remington JS, Klein J. Remington and Klein’s Infectious Diseases of the Foetus and Newborn Infant. 8th ed. Saunders; 2015.

Robert-Gangneux F, Dardé M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clinical microbiology reviews 2012;25 (2):264-296. DOI: 10.1128/CMR.05013-11.

Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. New England Journal of Medicine. 1974; 290 (20):1110-1116. DOI: 10.1056/NEJM197405162902003.

Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. Journal of Antimicrobial Chemotherapy. 1988; 22(Supplement B): 193-200. PMID: 3182443.

Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group 1, Lancet. 2007 Jan 13;369(9556):115-22. DOI: 10.1016/S0140-6736(07)60072-5.

Schoondermark-Van de Ven E, Galama J, Camps W et al. Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the foetus. Antimicrobial agents and chemotherapy. 1994; 38 (9):1922-1929. PMCID:PMC284663.

Dao A, Azzouz N, Nga CE et al. Unspecific reactivity of IgM directed against the low-molecular-weight antigen of Toxoplasma gondii. European Journal of Clinical Microbiology and Infectious Diseases. 2003; 22(7):418-421. DOI:10.1007/s10096-003-0948-9.

Gras L, Gilbert R, Wallon M et al. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiology and infection 2004; 132 (03):541-548. PMCID:PMC2870133.

Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. Journal of clinical microbiology 2004; 42 (3):941-945. PMCID: PMC356902.

Meroni V, Genco F, Tinelli C et al. Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies. Clinical and Vaccine Immunology 2009; 16(10):1517-1520. DOI: 10.1128/CVI.00253-09.

Hohlfeld P, Daffos F, Costa J-M et al. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. New England Journal of Medicine 1994; 331(11):695-699. DOI: 10.1056/NEJM199409153311102.

Faucher B, Garcia-Meric P, Franck J et al. Long-term ocular outcome in congenital toxoplasmosis: a prospective cohort of treated children. Journal of Infection 2012;64(1):104-109. DOI:10.1016/j.jinf.2011.10.008.

Gilbert RE, Thalib L, Tan HK et al. Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth. Journal of Medical Screening 2007;14 (1):8-13. DOI:10.1258/096914107780154440.

Rilling V, Dietz K, Krczal D et al. Evaluation of a commercial IgG/IgM Western blot assay for early postnatal diagnosis of congenital toxoplasmosis. European Journal of Clinical Microbiology and Infectious Diseases 2003; 22 (3):174-180.

McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clinical Infectious Diseases 1994; 18(1):38-72. PMID:8054436.

Robert- Gangneux F, Dupretz P, Yvenou C et al: Clinical Relevance of placenta examination for the diagnosis of congenital toxoplasmosis. Pediatr Infect Dis J 2010; 29:33-38. DOI: 10.1097/INF.0b013e3181b20ed1.

Sturge CR, Yarovinsky F. Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection. Infection and immunity 2014; 82 (8):3090-3097. DOI: 10.1128/IAI.01722-14.

Coombes J, Hunter C. Immunity to Toxoplasma gondii–into the 21st century. Parasite immunology 2015; 37 (3):105-107. DOI:10.1111/pim.12177.

Chapey E, Wallon M, Debize G et al. Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay. Journal of clinical microbiology 2010; 48(1):41-45. DOI:10.1128/JCM.01903-09.

Mahmoudi S, Mamishi S, Suo X, Keshavarz H. Early detection of Toxoplasma gondii infection by using a interferon gamma release assay: A review. Experimental parasitology 2017; 172:39-43. DOI:10.1016/j.exppara.2016.12.008.

Guglietta S, Beghetto E, Spadoni A et al. Age-dependent impairment of functional helper T cell responses to immunodominant epitopes of Toxoplasma gondii antigens in congenitally infected individuals. Microbes and infection 2007; 9 (2):127-133. DOI:10.1016/j.micinf.2006.10.017.

Downloads

Published

04/30/2018

Issue

Section

Review Articles